A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, Uncontrolled Asthma Patients with Eosinophilic Inflammation - SOLANA

Study identifier:D3250C00038

ClinicalTrials.gov identifier:NCT02869438

EudraCT identifier:2016-002094-36

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, Uncontrolled Asthma Patients with Eosinophilic Inflammation

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Benralizumab

Sex

All

Actual Enrollment

233

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 09 Nov 2016
Primary Completion Date: 01 Aug 2018
Study Completion Date: 01 Aug 2018

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 Oct 2019 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria